Pulmatrix, Inc. Stock price

Equities

PULM

US74584P3010

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.75 USD +8.02% Intraday chart for Pulmatrix, Inc. +6.21% -5.91%
Sales 2021 5.17M Sales 2022 6.07M Capitalization 14.12M
Net income 2021 -20M Net income 2022 -18M EV / Sales 2021 -5.21 x
Net cash position 2021 51.55M Net cash position 2022 34.77M EV / Sales 2022 -3.4 x
P/E ratio 2021
-1.01 x
P/E ratio 2022
-0.71 x
Employees 29
Yield 2021 *
-
Yield 2022
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer CI
Pulmatrix Explores Strategic Alternatives CI
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives DJ
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M MT
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole CI
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M MT
Sector Update: Health Care Stocks Easing Late Tuesday MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon MT
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise MT
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine CI
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $1.5M MT
More news
1 day+8.02%
1 week+6.21%
Current month-12.06%
1 month-14.63%
3 months-7.80%
6 months-12.94%
Current year-5.91%
More quotes
1 week
1.56
Extreme 1.5601
1.85
1 month
1.55
Extreme 1.55
2.05
Current year
1.55
Extreme 1.55
2.34
1 year
1.55
Extreme 1.55
3.15
3 years
1.55
Extreme 1.55
28.60
5 years
1.55
Extreme 1.55
60.80
10 years
1.55
Extreme 1.55
2 910.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 17-05-02
Director of Finance/CFO 68 22-04-17
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 56 19-10-31
Director/Board Member 54 20-06-22
Director/Board Member 53 20-09-30
More insiders
Date Price Change Volume
24-03-28 1.75 +8.02% 38 380
24-03-27 1.62 -4.18% 11,761
24-03-26 1.691 +1.24% 4,676
24-03-25 1.67 0.00% 7,597
24-03-22 1.67 +1.83% 3,013

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing inhaled therapies to address serious pulmonary diseases and central nervous system (CNS) disorders using its patented inhaled small particles easily respirable and emitted (iSPERSE) technology. Its inhaled therapeutic products based on its dry powder delivery technology, namely iSPERSE enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. Its iSPERSE's lead development program, PUR1900 is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. Its pipeline also includes PUR3100 for the treatment of acute migraine, and PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
More about the company
  1. Stock
  2. Equities
  3. Stock Pulmatrix, Inc. - Nasdaq